Immunovaccine Signs Research Agreement with Dana-Farber Cancer Institute

Immunovaccine Inc.(TSX-V:IMV), a vaccine development company, announced today that it has signed a collaborative agreement with the Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School.

The research collaboration involves formulating Dana-Farber’s HIV protein antigens in Immunovaccine’s DepoVax™ vaccine enhancement and delivery platform. The goal of this preclinical research is to establish whether this novel vaccine formulation will induce a stronger immune response.

Innovacorp Finalist for International Business Incubation Award

Innovacorp has once again been named one of two finalists in the National Business Incubation Association (NBIA) Incubation Program of the Year - 2010 competition.

The award recognizes the world's best methods to help new companies commercialize innovations and overcome hurdles to business growth. Innovacorp is a finalist alongside Emerging Technology Centers in Baltimore, Maryland.

Immunovaccine Begins Patient Recruitment for Phase I Trial of DPX-0907 Cancer Vaccine

Immunovaccine Inc. (TSX-V: IMV) today announced that it has started screening patients for its Phase I clinical trial, investigating the company’s therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. The primary goal of the trial is to establish the safety of the vaccine candidate which includes the DepoVax™ delivery platform. Secondary goals include an evaluation of dosing and an assessment of immune response.

EastMed Achieves National Health Coverage for uresta® Continence Care Product

EastMed Inc., an Atlantic Canadian medical manufacturing company that caters specifically to women's health and wellness, now has national health coverage for the uresta® Continence Care product.

Blue Cross recently agreed to cover the uresta® Continence Care product, joining other insurers Great West Life, ManuLife, and SunLife and ensuring national health coverage with all the major health insurers for this innovative women’s health product.

Sights & Sounds from the I-3 Competition Awards Event

On February 9, 2010, more than 250 Nova Scotians celebrated innovation and entrepreneurship in the province at the World Trade and Convention Centre in downtown Halifax. That evening, Innovacorp announced Tether as the provincial winner of the I-3 Technology Start-Up Competition, and celebrated the 1st and 2nd place award winners from the competition's five provincial zones. Check out the evening's sights and sounds.

I-3 Technology Start-Up Competition Provincial Winner Announced

Tether from Halifax was awarded a $100,000 seed investment from Innovacorp to build on its early business success.

Innovacorp announced Tether as the provincial winner of the I-3 Technology Start-Up competition, today, Feb. 9, at an event that marks the end of the five-month competition. (CLICK HERE FOR SIGHTS AND SOUNDS from the I-3 awards event.) 

Innovascreen and Saint Mary's University Partner to Advance Novel Brain Cancer Therapeutics

Innovascreen announces today an agreement with Saint Mary’s University to option the rights to a library of novel dacarbazine analogs, a promising class of alkylating agents similar to temozolomide, a first line therapy for an aggressive type of brain tumour known as glioblastoma. The option provides Innovascreen the rights to screen the library for lead compounds and conduct preclinical validation studies to determine safety and efficacy.

Pages

Subscribe to Innovacorp RSS